Academic literature on the topic 'Quality of life of patients with bronchial asthma'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Quality of life of patients with bronchial asthma.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Quality of life of patients with bronchial asthma"
1
Alikulova, Dilrabo, and Rixsi Salikhodjaeva. "EVALUATION OF QUALITY OF LIFE OF PATIENTS WITH PRIMARY BRONCHIAL ASTHMA IN THE HEALTH CARE SYSTEM." UZBEK MEDICAL JOURNAL 2, no. 4 (April 30, 2021): 51–54. http://dx.doi.org/10.26739/2181-0664-2021-4-8.
Full textAbstract:
The study of risk factors leading to the development of asthma, conducted in the form of a survey and interviews. 52% of patients with a diagnosis of asthma noted the presence of the disease among close relatives. Among the risk factors leading to bronchial asthma, the most common are pollen and tobacco (49.1%). 59.2% of patients diagnosed with asthma do not follow the diet. Keywords:asthma, nurses, primary health care, prevention, risk factors
2
Timoshina, Ye L., and S. B. Dugarova. "Quality of life: actual of problem and characteristics quality of life children with bronchial asthma." Bulletin of Siberian Medicine 8, no. 4 (August 28, 2009): 105–11. http://dx.doi.org/10.20538/1682-0363-2009-4-105-111.
Full text
3
Nalina, N., M. Chandra, and Umashankar. "Assessment of quality of life in bronchial asthma patients." International Journal of Medicine and Public Health 5, no. 1 (2015): 93. http://dx.doi.org/10.4103/2230-8598.151270.
Full text
4
Poliak, A., T. Vastchenko, V. Moiseenko, and K. Sulima. "New quality of life in patients with bronchial asthma." Patient Education and Counseling 23 (June 1994): S58. http://dx.doi.org/10.1016/0738-3991(94)90233-x.
Full text
5
Smetanenko, T. V., and O. S. Kobyakova. "Quality of life in patients having severe bronchial asthma." Bulletin of Siberian Medicine 4, no. 4 (December 30, 2005): 71–77. http://dx.doi.org/10.20538/1682-0363-2005-4-71-77.
Full text
6
Fassakhov, R. S. "Successful management of severe bronchial asthma: the right choice of biologic therapy in properly selected patients." Medical Council, no. 15 (December 8, 2019): 22–28. http://dx.doi.org/10.21518/2079-701x-2019-15-22-28.
Full textAbstract:
Severe asthma along with the impact on the quality of life of those suffering from this disease leads to significant medical and social damage. Studies of the last decade indicate the leading role of eosinophilic inflammation of the bronchi as the basis of the pathogenesis of the T2 phenotype of bronchial asthma, which led to the development of targeted therapy. The most effective in this direction were preparations of humanized monoclonal antibodies directed against the main pro-inflammatory cytokines involved in respiratory tract inflammation in bronchial asthma, one of the most significant among which is interleukin 5. Refinement of the definition of severe asthma, selection of these patients among patients with difficult to treat bronchial asthma allows to clearly determine the contingent with a predicted positive effect these highly effective drugs precision therapy. On clinical examples, the difference between difficult to treat and severe bronchial asthma is discussed. The stages of clinical trials of the preparation of monoclonal antibodies against interleukin 5 Mepolizumab are analyzed in detail, the search for effective prognostic biological markers available in normal practice, allowing to select patients suitable for the treatment of patients with severe eosinophilic bronchial asthma. The effectiveness of the approach based on the allocation of two threshold values of the number of eosinophils in the peripheral blood is convincingly confirmed by the results indicating a significant reduction in the number of exacerbations, improved of lung function and an increase of the quality of life in patients, including with steroiddependent bronchial asthma, obtained not only in randomized clinical studies, but also in studies in real clinical practice.
7
Andreeva, G. F., M. I. Smirnova, V. M. Gorbunov, A. S. Kurekhyan, and Ya N. Koshelyaevskaya. "Seasonal Indicators of Blood Pressure, Data of Asthma Control Questionnaires and Quality of Life in Hypertensive Patients with Bronchial Asthma." Rational Pharmacotherapy in Cardiology 15, no. 6 (January 3, 2020): 831–39. http://dx.doi.org/10.20996/1819-6446-2019-15-6-831-839.
Full textAbstract:
Aim. To study the seasonal indicators of quality of life and control of bronchial asthma in hypertensive patients with bronchial asthma, observed by a cardiologist of the state outpatient institution.Material and methods. Data from a prospective cohort study of hypertensive patients, some of which had bronchial asthma without exacerbation, were analyzed. Patients who were observed by a cardiologist at a state outpatient clinic took part in the study. There were other concomitant diseases that occurred in the participants, in addition to hypertension and bronchial asthma. Two groups of patients were formed: the control group (n=85) included patients with hypertension only, the main group (n=40) included hypertension and bronchial asthma. Patients had 3 visits: initial one, and after 6 and 12 months and then data on outcomes (30.1Ѓ}7.6 months of follow-up) were collected. The first and third visits included clinical measurements of blood pressure (BP), 24-hour BP monitoring, spirometry, clinical and biochemical blood tests, a standard survey, survey with questionnaires evaluating the control of bronchial asthma (Asthma Control Questionnaire; ACQ) and the patients quality of life (General Well-Being Questionnaire; GWBQ). The second visit included clinical BP and ACQ and GWBQ questionnaires. A comparison of the average indicators from the total number of observations carried out in winter, spring, summer and autumn periods has been performed.Results. Hypertensive patients with/without bronchial asthma (n=125; 28 men, 97 women, average age 62.6Ѓ}8.8 years, duration of hypertension – 11.6Ѓ}8.6, duration of bronchial asthma – 9.3Ѓ}11.9 years) took part in the study. Outpatient BP levels throughout the study period were maintained at target values in both groups. It was shown that seasonal BP levels do not differ in the compared groups, except for winter indicators: winter daytime systolic BP levels were higher in the main group (p=0.03). Seasonal fluctuations in BP were not detected in the control group, however, they were present in the patients of the main group: winter daytime levels of diastolic BP and average daily levels of diastolic BP and systolic BP were higher than summer ones, and winter daytime systolic BP values (p<0.05) and clinical diastolic BP (p=0.004) – higher than autumn levels. Seasonal quality of life indicators in the main group were worse than in the control group in all seasons. Significant seasonal dynamics of quality of life indicators in patients in two groups was not detected. The ACQ questionnaire showed that asthma control changed in different seasons in accordance with the ACQ total score: in winter and spring – uncontrolled bronchial asthma (total score >1.5), in summer and autumn – partially controlled (total score ≤1.5). During the analysis of various factors associated with the combined primary endpoint (death, transient ischemic attack, angina pectoris, cardiac arrhythmias, arterial revascularization), relationships with quality of life indicators were revealed: negative connections – with indicators characterizing positive psychological health, mood at visit, positive correlations – with psychological abilities.Conclusion: Seasonal fluctuations in ambulatory BP levels were not found in the control group and were found in the main group. The quality of life indicators for patients of the main group were significantly worse than in the control group for all components in all seasons. The control of asthma changed in different seasons in accordance with the ACQ total score: uncontrolled bronchial asthma occurred in winter and spring, partially controlled – in summer and autumn. Correlations of the combined primary endpoint with quality of life indicators were found after analyzing various factors.
8
Faye, A. D., S. Gawande, R. Tadke, V. C. Kirpekar, S. H. Bhave, A. P. Pakhare, and B. Tayade. "Do Panic Symptoms Affect the Quality of Life and Add to the Disability in Patients with Bronchial Asthma?" Psychiatry Journal 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/608351.
Full textAbstract:
Background. Anxiety and panic are known to be associated with bronchial asthma with variety of impact on clinical presentation, treatment outcome, comorbidities, quality of life, and functional disability in patients with asthma. This study aims to explore the pattern of panic symptoms, prevalence and severity of panic disorder (PD), quality of life, and disability in them.Methods. Sixty consecutive patients of bronchial asthma were interviewed using semistructured proforma, Panic and Agoraphobia scale, WHO Quality of life (QOL) BREF scale, and WHO disability schedule II (WHODAS II).Results. Though 60% of the participants had panic symptoms, only 46.7% had diagnosable panic attacks according to DSM IV TR diagnostic criteria and 33.3% had PD. Most common symptoms were “sensations of shortness of breath or smothering,” “feeling of choking,” and “fear of dying” found in 83.3% of the participants. 73.3% of the participants had poor quality of life which was most impaired in physical and environmental domains. 55% of the participants had disability score more than a mean (18.1).Conclusion. One-third of the participants had panic disorder with significant effect on physical and environmental domains of quality of life. Patients with more severe PD and bronchial asthma had more disability.
9
Zaikina, Yulia, Nataliia Cherednichenko, Hanna Tymchenko, Gennadii Kochuiev, and Maryna Kochuieva. "Evaluation of the obesity influence on the life quality in patients with bronchial asthma." EUREKA: Health Sciences, no. 3 (May 25, 2021): 31–36. http://dx.doi.org/10.21303/2504-5679.2021.001842.
Full textAbstract:
The obese asthma is characterized by a more severe course. The feature of this comorbid condition is the reduced effectiveness of basic therapy with inhaled corticosteroids, which prevents optimal control of symptoms, requires increasing doses and increases the number of exacerbations and hospitalizations. The problem of life quality (LQ) research in patients with asthma and obesity is highly relevant today, which made it the reason for this study.
The aim of the study was to determine the effect of obesity on LQ in patients with asthma.
Materials and methods. We selected for participating in the study 46 patients with moderate severity asthma. Examination of the patients included: objective examination with an anthropometric evaluation, the test of the LQ with two questionnaires: general one – Medical Outcome Study SF-36 (MOS SF-36) and specialized Asthma Quality of Life Questionnaire (AQLQ).
Results. The increase in body mass index (BMI) in patients with asthma according to the questionnaires MOS SF-36 and AQLQ is associated with significant reductions in viability (r=–0.33, p<0.05), physical activity (r=–0.37, p<0.01), social activity (r=–0.36, p <0.01) and the degree of reduction of the patient's tolerance to adverse environmental factors (r=–0.29, p<0.05)
Conclusions. The presence of concomitant obesity in patients with asthma is associated with significant reductions in the parameters of physical and social activity, viability and with an increase in the subjective pain assessment (according to the questionnaire MOS SF-36) and characterized by significantly lower rates of activity, tolerance to adverse environmental factors and general life quality (according to the AQLQ questionnaire).
10
Korkmazov, M. Yu, M. A. Lengina, I. D. Dubinets, A. M. Korkmazov, and A. A. Smirnov. "Opportunities for correction of individual links of the pathogenesis of allergic rhinitis and bronchial asthma with assessment of the quality of life of patients." Meditsinskiy sovet = Medical Council, no. 4 (April 5, 2022): 24–34. http://dx.doi.org/10.21518/2079-701x-2022-16-4-24-34.
Full textAbstract:
Introduction. One of the antileukotriene drugs for the treatment of bronchial asthma and allergic rhinitis with and without polyposis is montelukast. The presented article presents the results of the analysis of the effectiveness, safety and impact on the quality of life of patients, the use of the singular, in various forms of allergic rhinitis and associated comorbid conditions.Aim of the study. To assess the impact on the quality of life of patients, the effectiveness and safety of the use of montelukast in the complex therapy of patients with allergic rhinitis and comorbid diseases.Materials and methods. A simple, blind, randomized, controlled clinical trial involved 97 patients divided into 4 groups: patients with moderate allergic rhinitis; allergic rhinitis of moderate severity and bronchial asthma; severe allergic rhinitis and bronchial asthma; severe allergic rhinitis, bronchial asthma and polypous rhinosinusitis. In parallel with the comparison of drug tolerability, safety and clinical symptoms (rhinorrhea, nasal congestion, itching, sneezing, bronchopulmonary manifestations), the quality of life was assessed using a special SNOT-22 questionnaire.Results. The use of the antileukotriene drug montelukast in the complex therapy of allergic rhinitis and related comorbid conditions significantly improved the clinical symptoms and quality of life of patients over the entire period of treatment in all groups. There was an increase in the suppression of leukotriene-mediated effects when using montelukast, more in the group of people with allergic rhinitis and bronchial asthma, such as symptoms of the allergic triad, mucus hypersecretion, bronchospasm, eosinophilia, increased vascular permeability, etc.Conclusion. In the treatment of patients with allergic rhinitis and morbid conditions, Singular has demonstrated an inhibitory effect on cysteinyl leukotrienes, high bioavailability, good tolerability and safety.
Dissertations / Theses on the topic "Quality of life of patients with bronchial asthma"
1
Ehrs, Per Olof. "Quality of life and markers of inflammation : a study of asthma in primary care /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-539-9/.
Full text
2
Drummond, Neil. "Quality of life for asthma patients : an existential-aesthetic theory." Thesis, University of Aberdeen, 1997. http://digitool.abdn.ac.uk/R?func=search-advanced-go&find_code1=WSN&request1=AAIU602298.
Full textAbstract:
Aim: It was the aim of the present study to investigate in detail and at length the experience of quality in a life with asthma, within the perspective of those suffering from the disease rather than those with a professional interest in it. Method: An ethnographic method was adopted, consisting of three semi-structured interviews with a sample of 22 moderately severe asthma patients referred to consultant respiratory physicians in Aberdeen, Scotland. Potential interviewees, stratified by age, sex and social class, were invited to participate after they had completed their year in the Grampian Asthma Study of Integrated Care (GRAS SIC 1994a). After a minimum delay of eight months following their exit from GRAS SIC, interviews were conducted in their homes, were audio recorded, selectively transcribed, and subjected to content analysis. Conclusions and implications: Identifying quality of life with asthma as an existential concept aesthetically understood and therefore unpredictably variable has serious implications for its use in clinical practice, health care planning and purchasing, and research. Professional judgements about the outcome of treatment for individual asthma patients should incorporate that patient's valuation of that outcome: what may to the professional be highly desirable treatment effects may be irrelevant to the person within whom they are observed. Similarly, planning and purchasing health care for asthma on the basis of data which do not incorporate the value judgements of the users of services may lead to the provision of insignificant levels and types of care for specific communities and a failure to provide care or services for which the community has a true value. Each of these effects derives from the difficulty of validly measuring so unstable an outcome. Research into quality of life should concentrate upon the task of devising outcome measurement methods which directly, accurately and meaningfully incorporate patient-held values. The difficulty of doing so should not be underestimated. A clear distinction should be drawn between methods which measure an aspect (or aspects) of health status and those which reflect quality of life. These two concepts are not identical, and care should be taken that the terms are used independently, specifically and without ambiguity. Health status describes the physical, mental or social functioning of the individual within their condition or state. To use health status measures to validate assessment of life quality is to misconceive the nature of their relationship. Quality of life refers to the all-embracing subjective value of the human condition.
3
Hernández, Pombo María Gimena. "Treatment safety, adherence and health-related quality of life in patients with asthma." Doctoral thesis, Universitat Autònoma de Barcelona, 2018. http://hdl.handle.net/10803/666784.
Full textAbstract:
L'objectiu general d'aquesta tesi doctoral va ser avaluar la qualitat de vida relacionada amb la salut (QVRS) en pacients amb asma i els factors sociodemogràfics i clínics que contribueïxen al seu deteriorament. També, avaluar la seguretat dels broncodilatadors d'acció llarga (BAL) combinats amb corticosteroides inhalats (CI) i els determinants de l'adherència al tractament.
L’evidència obtinguda en estudis observacionals (recerca sistemàtica en MEDLINE i EMBASE, període 1990-2013, incloent 19 estudis amb graandàries mostrals entre 50 i 514.216), mostren que el tractament combinat de LABA i CI no està associat a un major risc d'esdeveniments adversos greus, en comparació amb només CI. Els principals dèficits identificats van ser la mancança de disseny prospectiu, de població pediàtrica i de inclusió de la mortalitat com a resultat primari. Una revisió sistemàtica dels estudis observacionals sobre els determinants de l'adherència als inhaladors per a l‘asma va identificar 51 estudis (cerca realitzada a EMBASE, Medline, PsychInfo i PsychArticles de 1990 a 2014) que van examinar principalment els factors relacionats amb el pacient, i van trobar associacions consistents entre l’adherència i creences més arralades en la necessitat dels inhaladors, i possiblement amb una edat més avançada. Es va detectar la necessitat d'una amplia adopció d'estàndards conceptuals i metodològics comuns.
El projecte titulat “Assessment of the Safety of LABAs in asthma in routine care by combining health care data bases and direct patient-follow-up” (ASTRO-LAB) va ser un estudi prospectiu longitudinal (n = 908 pacients). Els pacients es van reclutar en els centres d’atenció primària a França i el Regne Unit. Els criteris d'inclusió eren: individus de 6 a 40 anys d'edat amb asma persistent, definit com més de 6 mesos de prescripció de CI i/o BAL durant els 12 mesos previs al seu reclutament. L'anàlisi dels 290 pacients que van completar l'EQ-5D-5L en l'enquesta basal per internet va demostrar un efecte sostre acceptable, una bona validesa de constructe i una alta fiabilitat, donant suport a la idoneitat d'aquesta nova versió del EQ-5D per avaluar la QVRS en pacients amb asma.
Finalment, vam comparar els pacients francesos (n = 222) amb les normes de referència EQ-5D procedents de França per estimar l'impacte de l'asma en la QVRS del pacient. L'asma persistent té un impacte moderadament negatiu en els pacients d'ambdós sexes, i les dones més joves van ser identificades com un grup d'alt risc que mereix més recerca. Hem identificat el control de l'asma com a principal factor associat de la reducció de la QVRS en els pacients, independentment del seu gènere, el que suggereix que l'impacte de l‘asma en la QVRS es podria mitigar aconseguint un bon control dels símptomes.El objetivo general de esta tesis doctoral fue evaluar la calidad de vida relacionada con la salud (CVRS) en pacientes con asma y los factores sociodemográficos y clínicos que contribuyen a su deterioro. Asimismo, evaluar la seguridad de los broncodilatadores de acción larga (BAL) combinados con corticosteroides inhalados (CI) y los determinantes de la adherencia al tratamiento. La evidencia obtenida en los estudios observacionales (búsqueda sistemática en MEDLINE y EMBASE, período 1990-2013, incluyó 19 estudios de tamaños muestrales entre 50 y 514.216) demuestra que el tratamiento combinado de BAL y CI no se asocia con un mayor riesgo de eventos adversos graves, en comparación con el tratamiento sólo con CI. Los principales déficits identificados fueron la falta de diseño prospectivo, de población pediátrica y de mortalidad como resultado primario. La revisión sistemática de estudios observacionales sobre determinantes de la adherencia a los inhaladores para el asma identificó 51 estudios (búsqueda realizada en EMBASE, Medline, PsychInfo y PsychArticles entre 1990 y 2014) que examinaron principalmente los factores relacionados con el paciente y encontraron una relación consistente entre la adherencia y las creencias más arraigadas en la necesidad de inhaladores, y posiblemente con una edad más avanzada. Se detectó la necesidad de una adopción más amplia de estándares conceptuales y metodológicos comunes. El proyecto titulado “Assessment of the Safety of LABAs in asthma in routine care by combining health care data bases and direct patient-follow-up” (ASTRO-LAB) fue un estudio longitudinal prospectivo (n = 908 pacientes). Los pacientes fueron reclutados en centros de atención primaria en Francia y Reino Unido. Los criterios de inclusión fueron: individuos cuyas edades estaban comprendidas entre los 6 y 40 años con asma persistente, definido como más de 6 meses de prescripción de CI y/o BAL durante los 12 meses anteriores al reclutamiento. El análisis de los 290 pacientes que completaron el EQ-5D-5L en la encuesta basal por internet demostró un efecto techo aceptable, una buena validez de constructo y una alta fiabilidad, lo cual apoya la idoneidad de esta nueva versión del EQ-5D para evaluar la CVRS en pacientes con asma. Finalmente, comparamos los pacientes franceses (n = 222) con las normas de referencia del EQ-5D en Francia para estimar el impacto del asma en la CVRS de los pacientes. El asma persistente tiene un impacto en la CVRS moderadamente negativo en pacientes de ambos sexos, y las mujeres más jóvenes fueron identificadas como un grupo de alto riesgo que merece más investigación. Identificamos el control del asma como el principal factor asociado al deterioro de la CVRS en los pacientes, independientemente de su sexo, lo que sugiere que el impacto del asma en la CVRS se podría mitigar logrando un buen control de los síntomas.
The general aim of this doctoral thesis was to evaluate the health-related quality of life (HRQoL) in patients with asthma, and the socio-demographic and clinical factors which contributed to its impairment. Also, to assess the safety of long-acting beta-agonists (LABAs) combined with inhaled corticosteroids (ICs), and the determinants of treatment adherence. Evidence from observational studies (systematic search in MEDLINE and EMBASE, period 1990-2013, including 19 studies with sample sizes from 50 to 514,216) shows that the combined treatment of LABAs and ICs is not associated with a higher risk of serious adverse events, compared to ICs alone. Major gaps identified were: prospective design, paediatric population and inclusion of mortality as a primary outcome. The systematic review of observational studies on determinants of asthma inhaler adherence identified 51 studies (search performed in EMBASE, Medline, PsychInfo and PsychArticles from 1990 to 2014) which mainly examined patient-related factors and found consistent links between adherence and stronger beliefs in inhaler necessity, and possibly with older age. The need of a broader adoption of common conceptual and methodological standards was detected. The project entitled “Assessment of the Safety of LABAs in asthma in routine care by combining health care data bases and direct patient-follow-up” (ASTRO-LAB) was a prospective longitudinal study (n= 908 patients). Patients were enrolled in primary care in France and United Kingdom by their general practitioner. Inclusion criteria were: subjects aged 6-40 years old, with persistent asthma, defined as more than 6 months of prescribed ICs and/or LABAs during 12 months before inclusion. Analysis of the 290 patients who completed the EQ-5D-5L in the baseline online survey demonstrated acceptable ceiling effect, good construct validity, and high reliability, supporting the adequacy of this new EQ-5D version for assessing HRQoL in asthma patients. Finally, French patients (n= 222) were compared with the EQ-5D reference norms from France to estimate the impact of asthma on patients' HRQoL. Persistent asthma has a moderately negative HRQoL impact on patients of both genders, and the youngest women have been identified as a high risk group which merits further research. We identified asthma control as the major factor associated to impaired HRQoL in patients, regardless of their gender, suggesting that asthma HRQoL impact could be alleviated by achieving a good symptom control.
4
Capstick, Toby Gareth David. "The effectiveness of pharmacist interventions in improving asthma control and quality of life in patients with difficult asthma." Thesis, University of Bradford, 2014. http://hdl.handle.net/10454/13962.
Full textAbstract:
Despite national guidelines, the management of difficult asthma remains suboptimal, and there may be opportunities for pharmacists to improve asthma outcomes. This six-month prospective, randomised, open study investigated the effects of pharmaceutical care across primary and secondary care on difficult asthma. Fifty-two patients attending a hospital difficult asthma clinic were randomised (1:1) to receive usual medical care (UC), or pharmacist interventions (PI) comprising asthma review, education, and medicines optimisation from a hospital advanced clinical pharmacist, plus follow-up targeted Medicines Use Review (t-MUR) from community pharmacists. Forty-seven patients completed the study. More interventions were performed in the PI group at baseline (total 79 vs. 34, p<0.001), but only six patients received a t-MUR. At six-months, PI were non-inferior to UC for all outcomes. The primary outcome measure was Juniper’s Asthma Control Questionnaire score and reduced (improved) from a median (IQ) score of 2.86 (2.25, 3.25) and 3.00 (1.96, 3.71) in the PI and UC groups respectively to 2.57 (1.75, 3.67) and 2.29 (1.50, 3.50). At baseline, 58.8%, 46.9% and 17.6% of patients had optimal inhaler technique using Accuhalers, Turbohalers or pMDIs; education improved technique but this was not maintained at six-months. Adherence rates < 80% were observed in 57.5% of patients at baseline, and was improved in the PI group at six-months (10/20 PI vs. 3/21 UC had adherence rates of 80-120%, p=0.020). This study demonstrates that the management of difficult asthma by specialist pharmacists is as effective as usual medical care. Future research should investigate whether pharmacist-led follow-up produces further improvements.
5
Capstick, Toby G. D. "The Effectiveness of Pharmacist Interventions in Improving Asthma Control and Quality of Life in Patients with Difficult Asthma." Thesis, University of Bradford, 2014. http://hdl.handle.net/10454/13962.
Full textAbstract:
Despite national guidelines, the management of difficult asthma remains suboptimal, and there may be opportunities for pharmacists to improve asthma outcomes. This six-month prospective, randomised, open study investigated the effects of pharmaceutical care across primary and secondary care on difficult asthma.
Fifty-two patients attending a hospital difficult asthma clinic were randomised
(1:1) to receive usual medical care (UC), or pharmacist interventions (PI) comprising asthma review, education, and medicines optimisation from a hospital advanced clinical pharmacist, plus follow-up targeted Medicines Use Review (t-MUR) from community pharmacists.
Forty-seven patients completed the study. More interventions were performed in the PI group at baseline (total 79 vs. 34, p<0.001), but only six patients received a t-MUR. At six-months, PI were non-inferior to UC for all outcomes. The primary outcome measure was Juniper’s Asthma Control Questionnaire score and reduced (improved) from a median (IQ) score of 2.86 (2.25, 3.25) and 3.00 (1.96, 3.71) in the PI and UC groups respectively to 2.57 (1.75, 3.67) and 2.29 (1.50, 3.50).
At baseline, 58.8%, 46.9% and 17.6% of patients had optimal inhaler technique using Accuhalers, Turbohalers or pMDIs; education improved technique but this was not maintained at six-months. Adherence rates <80% were observed in 57.5% of patients at baseline, and was improved in the PI group at six-months (10/20 PI vs. 3/21 UC had adherence rates of 80-120%, p=0.020).
This study demonstrates that the management of difficult asthma by specialist pharmacists is as effective as usual medical care. Future research should investigate whether pharmacist-led follow-up produces further improvements.The Pharmaceutical Trust for Educational and Charitable Objects (PTECO) (now known as Pharmacy Research UK).
6
Chen, Wenjia. "Longitudinal studies of disease progression, health care costs and health-related quality of life in patients with asthma." Thesis, University of British Columbia, 2016. http://hdl.handle.net/2429/59297.
Full textAbstract:
This thesis examines the burden of asthma and its determinants though a series of longitudinal observational studies. Objectives: 1) To quantify the natural history of severe asthma and the impact of early risk factors; 2) To examine the influence of socioeconomic status (SES) on excess direct medical costs of moderate-to-severe asthma and guideline-based asthma care; 3) To estimate excess costs of asthma and the economic implications of comorbidities; 4) To assess the joint influences of asthma control and comorbidity on health-related quality of life. Methods: For the first three objectives, administrative health data (for the period of 1997-2013) were obtained from British Columbia (BC) Ministry of Health, and for the last objective data were obtained from the Economic Burden of Asthma (EBA) study in BC. Various models for longitudinal data were applied for each objective. Findings: 1) Most patients (83%) with incident severe asthma transitioned to milder states after 10 years. Low SES and comorbidity at disease onset led to worse long-term prognosis. 2) Across both individual- and neighborhood-levels, there was evidence that low-SES asthma patients and/or their care providers did not follow guideline-based asthma care and subsequently incurred substantially greater excess costs of asthma. 3) Excess costs in patients with asthma were $1187/year (95%CI $1130─$1243) overall, with comorbidity-attributable costs five times higher than asthma-attributable costs, all of which greatly increased with age. 4) Changes in asthma control had a greater effect on disease-specific (AQ5D) than generic (EQ5D) utilities, whereas changes in comorbidity burden had a larger impact on EQ5D than AQ5D utilities. Conclusions: With several novel methodology techniques, this thesis provided evidence for the first-time on the long-term trajectory and burden of asthma. Projection of cost and effectiveness of decisions and policies in asthma care requires a robust understanding of the natural history of asthma, effect of risk factors on this trajectory, and estimates of costs and health-related quality of life associated with asthma. This thesis provides new evidence on all such parameters. These findings have direct relevance to estimating cost-effectiveness of health technologies in asthma and can result in more informed decision-making in health policy and clinical practice.Pharmaceutical Sciences, Faculty of
Graduate
7
Senavaitytė, Asta. "Sergančiųjų bronchų astma gyvenimo kokybės įvertinimas." Master's thesis, Lithuanian Academic Libraries Network (LABT), 2005. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2005~D_20050616_123849-27371.
Full textAbstract:
Summary
Bronchial asthma (BA) is considered to be the disease of civilization. Life conditions of the people improve and liability to alergies becomes more intensive. Air polution determines, that asthma spreads fastly in all the world and has become a world problem of health. Asthma has exacerbated quality of life of many asthmatic people: it causes discomfort, psychological tension. Financial losses are much easier beared by a patient than social barrier, however, poor financial situation influences deeply the quality life of the asthmatic people.
The goal of this work: to estimate the quality of life of asthmatic people.
The following tasks have been set up in achieving this goal:
1. To evaluate the quality of life of astmatic people using SGPQ.
2. To evaluate the influence of BA to patient’s quality of life;
3. To define training impact of BA to quality of life.
Investigations have been carried out using SGPQ. 100 patients - asthmatic people have been interviewed according to unanimous questionnarie for no less than one year. Totally the interview have passed 53 men and 47 women, i.e. 53 percentage of men and 47 percentage of women of totally interviewed. Age census of both gender groups was from 18 till 75 years old. Accordingly, the average age of the investigated group was 49,8. Hence, while evaluating harm character of QL, the patients pointed, that the following symptoms mostly disorganize their quality of life (defined calculated interval –... [to full text]
8
Ammari, Wasem G. S. "Evaluation of novel tool to ensure asthma and COPD patients use the approved inhalation technique when they use an inhaler. Clinical pharmacy studies investigating the impact of novel inhalation technique training devices and spacers on the inspiratory characteristics, disease control and quality of life of patients when using their inhalers." Thesis, University of Bradford, 2010. http://hdl.handle.net/10454/4422.
Full textAbstract:
Many respiratory patients misuse their inhaler. Although training improves their inhaler technique, patients do forget the correct inhaler use with time. In the current work, three clinical studies investigated novel tools designed with feedback mechanisms to ensure patients use the correct inhalation method when using their inhaler. Research Ethics Committee approval was obtained and all the participants signed an informed consent form.
In the first study, the recruited asthmatic children (n=17) and adults (n=39) had their metered dose inhaler (MDI) technique assessed. Those who attained the recommended inhalation flow rate (IFR) of < 90 l/min through their MDI formed the control group. Whilst those who had a poor MDI technique with an IFR ¿ 90 l/min were randomized into either the verbal counselling (VC) group; or the 2ToneTrainer (2TT) group that, in addition to the verbal training, received the 2ToneTrainer MDI technique training device equipped with an audible feedback mechanism of correct inhalation flow. All the participants were assessed on two occasions (6 weeks apart) for their inhalation flow rate, asthma control and quality of life. The study showed that the 2ToneTrainer tool was as efficient as verbal training in improving and maintaining the asthmatic patients¿ MDI technique, particularly using the recommended slow inhalation flow through the MDI. Although statistically insignificant, potential improvement in quality of life was demonstrated. The 2ToneTrainer tool has the advantage of being available to the patients all the time to use when they are in doubt of their MDI technique.
In the second research study, the inhalation profiles of asthmatic children (n=58) and adults (n=63), and of COPD patients (n=63) were obtained when they inhaled through the novel Spiromax dry powder inhaler (DPI) which was connected to an electronic pressure change recorder. From these inspiratory profiles; the peak inhalation flow, inhalation volume and inhalation acceleration rate were determined. The variability (23% - 58%) found in these inhalation profile parameters among various patient groups would be expected in all DPIs. The effect of the inhalation acceleration rates and volumes on dose emission characteristics from DPIs should be investigated. Attention, though, should be paid to the patients¿ realistic inhalation profile parameters, rather than the recommended Pharmacopoeial optimal inhalation standard condition, when evaluating the in-vitro performance of DPIs.
Finally, in preschool asthmatic children, the routine use of the current AeroChamber Plus spacer (n=9) was compared with that of a novel version; the AeroChamber Plus with Flow-Vu spacer (n=10) over a 12-week period. The Flow-Vu spacer has a visual feedback indicator confirming inhalation and tight mask-face seal. The study showed that the new AeroChamber Plus with Flow-Vu spacer provided the same asthma control as the AeroChamber Plus in preschool children and maintained the same asthma-related quality of life of their parents. However, the parents preferred the new Flow-Vu spacer because its visual feedback indicator of inhalation reassured them that their asthmatic children did take their inhaled medication sufficiently.
9
Ammari, Wasem Ghazi Saleem. "Evaluation of novel tool to ensure asthma and COPD patients use the approved inhalation technique when they use an inhaler : clinical pharmacy studies investigating the impact of novel inhalation technique training devices and spacers on the inspiratory characteristics, disease control and quality of life of patients when using their inhalers." Thesis, University of Bradford, 2010. http://hdl.handle.net/10454/4422.
Full textAbstract:
Many respiratory patients misuse their inhaler. Although training improves their inhaler technique, patients do forget the correct inhaler use with time. In the current work, three clinical studies investigated novel tools designed with feedback mechanisms to ensure patients use the correct inhalation method when using their inhaler. Research Ethics Committee approval was obtained and all the participants signed an informed consent form. In the first study, the recruited asthmatic children (n=17) and adults (n=39) had their metered dose inhaler (MDI) technique assessed. Those who attained the recommended inhalation flow rate (IFR) of < 90 l/min through their MDI formed the control group. Whilst those who had a poor MDI technique with an IFR ≥ 90 l/min were randomized into either the verbal counselling (VC) group; or the 2ToneTrainer (2TT) group that, in addition to the verbal training, received the 2ToneTrainer MDI technique training device equipped with an audible feedback mechanism of correct inhalation flow. All the participants were assessed on two occasions (6 weeks apart) for their inhalation flow rate, asthma control and quality of life. The study showed that the 2ToneTrainer tool was as efficient as verbal training in improving and maintaining the asthmatic patients' MDI technique, particularly using the recommended slow inhalation flow through the MDI. Although statistically insignificant, potential improvement in quality of life was demonstrated. The 2ToneTrainer tool has the advantage of being available to the patients all the time to use when they are in doubt of their MDI technique. In the second research study, the inhalation profiles of asthmatic children (n=58) and adults (n=63), and of COPD patients (n=63) were obtained when they inhaled through the novel Spiromax dry powder inhaler (DPI) which was connected to an electronic pressure change recorder. From these inspiratory profiles; the peak inhalation flow, inhalation volume and inhalation acceleration rate were determined. The variability (23%-58%) found in these inhalation profile parameters among various patient groups would be expected in all DPIs. The effect of the inhalation acceleration rates and volumes on dose emission characteristics from DPIs should be investigated. Attention, though, should be paid to the patients' realistic inhalation profile parameters, rather than the recommended Pharmacopoeial optimal inhalation standard condition, when evaluating the in-vitro performance of DPIs. Finally, in preschool asthmatic children, the routine use of the current AeroChamber Plus spacer (n=9) was compared with that of a novel version; the AeroChamber Plus with Flow-Vu spacer (n=10) over a 12-week period. The Flow-Vu spacer has a visual feedback indicator confirming inhalation and tight mask-face seal. The study showed that the new AeroChamber Plus with Flow-Vu spacer provided the same asthma control as the AeroChamber Plus in preschool children and maintained the same asthma-related quality of life of their parents. However, the parents preferred the new Flow-Vu spacer because its visual feedback indicator of inhalation reassured them that their asthmatic children did take their inhaled medication sufficiently.
10
Pinto, Andrezza França. "Efeito do treinamento físico aeróbio na hiperresponsividade brônquica e no processo inflamatório pulmonar de pacientes com asma moderada a grave." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5146/tde-11082014-142514/.
Full textAbstract:
Introdução: A asma é caracterizada por um processo inflamatório crônico que está associado ao desenvolvimento da hiperresponsividade brônquica (HRB). O exercício físico regular proporciona inúmeros benefícios aos pacientes com asma porém, os efeitos do treinamento físico na HRB permanecem pouco compreendidos. Objetivo: Avaliar o efeito do treinamento físico aeróbio na hiperresponsividade brônquica, inflamação pulmonar, controle clínico e fatores relacionados à qualidade de vida de pacientes adultos com asma persistente moderada a grave. Métodos: Cinquenta e oito adultos com asma moderada a grave foram divididos aleatoriamente, em dois grupos: Controle (GC, n=28) e Treinado (GT, n=30). Os pacientes do GC foram submetidos a um programa educacional e a um programa de exercícios respiratórios, enquanto os pacientes do GT foram submetidos a todos os procedimentos do GC e a um programa de condicionamento físico aeróbio. A hiperresponsividade brônquica foi avaliada através do teste de broncoprovocação inespecífica com histamina antes e após a intervenção. Nestas ocasiões, todos os pacientes também realizaram, análise do escarro induzido e da fração exalada de óxido nítrico, espirometria, teste ergoespirométrico e responderam aos questionários de controle clínico, fatores de saúde relacionados à qualidade de vida (FSRQV) e níveis de depressão. Além disso, foi coletada uma amostra do sangue venoso dos pacientes para quantificação do IgE total e de IgE específica. Resultados: Após três meses de intervenção, os pacientes do GT aumentaram 1 dupla dose de concentração (dd) (1 dd; 0,3-1,7 dd, 95% CI) (p < 0,05) enquanto o GC (0,06 dd; -0,6dd a 0,7 dd, 95% CI) não apresentou mudança significativa na hiperresponsividade brônquica. A inflamação pulmonar reduziu apenas nos pacientes do GT que apresentaram níveis elevados de eosinófilos (> 3%) e FeNO (> 26ppb) (p < 0,05). O condicionamento aeróbio melhorou os FSRQV, controle clínico da asma e níveis de depressão (p < 0,05). Conclusão: Nossos resultados demonstram que o treinamento aeróbio tem um efeito anti-inflamatório importante na asma e deve ser considerado como um tratamento complementar para o manejo da doençaIntroduction: Asthma is characterized by a chronic inflammatory process that is associated with the development of bronchial hyperresponsiveness (BHR). Regular exercise provides numerous benefits in patients with asthma; however, the effects of exercise training on BHR remain poorly understood. Objective: To evaluate the effect an aerobic training on bronchial hyperresponsiveness, pulmonary inflammation, clinical control and health related quality of life (HRQoL) in adults patients with moderate to severe asthma. Methods: Fifty-eigth patients adults with moderate to severe asthma were randomly assigned into two groups: Control (CG, n = 28) and Trained (TG, n = 30).The GC patients undertake an educational program and performed breathing exercises, while the TG patients underwent the same procedures than CG plus an aerobic training program. Bronchial hyperresponsiveness was assessed by nonspecific bronchial provocation test with histamine before and after the intervention. On these occasions, all patients also performed induced sputum analysis and fractional exhaled nitric oxide (FeNO), spirometry, cardiopulmonary exercise testing and fulfilled questionnaires to evaluate clinical control test, HRQoL and depression levels. In addition, blood samples were collect in order to quantify total serum immunoglobulin (IgE) and specific IgE. Results: After 3 months of intervention, the TG increased 1 double dose of concentration (dd) (0.3 to 1.7 dd, 95% IC) and CG did not change significantly on bronchial hyperresponsiveness 0.06 dd (-0.6 to 0.7 dd, 95% IC) (p < 0.05).The pulmonary inflammation reduced only in the GT patients with high levels of eosinophils (> 3%) and FeNO (> 26ppb) (p < 0.05). Aerobic training also improved HRQoL, clinical control and depression levels (p < 0.05).Conclusion: Our results demonstrate that aerobic training exercise has a significant anti-inflammatory effect on asthma and should be considered as a complementary treatment for disease management
Books on the topic "Quality of life of patients with bronchial asthma"
1
Launois, Sandrine H., and Patrick Lévy. Pulmonary disorders and sleep. Edited by Sudhansu Chokroverty, Luigi Ferini-Strambi, and Christopher Kennard. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199682003.003.0041.
Full textAbstract:
Sleep disorders and pulmonary diseases are closely associated, a fact clearly underestimated in routine patient care, despite evidence that these disorders interact to impact on quality of life as well as on morbidity and mortality. The prevalence of chronic insomnia, sleep-related breathing disorders, and restless leg syndrome is high in patients with chronic pulmonary disorders such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, chest wall and neuromuscular disorders, and chronic respiratory failure. This association may be fortuitous and reflect the impact of a chronic condition on sleep quality, or it may be due to specific sleep-related phenomena adversely affecting an underlying pulmonary disorder. Furthermore, obstructive sleep apnea has been implicated as a risk factor for pulmonary hypertension and pulmonary embolism. This chapter outlines the implications for both pulmonary and sleep specialists, in terms of clinical management and treatment strategies.
2
Rao, Seema. Integrated Approaches to Treating Lung Diseases in the Geriatric Population. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190466268.003.0018.
Full textAbstract:
Structural and functional changes in the aging lung and body predispose the older patient to pulmonary diseases such as asthma, chronic obstructive pulmonary disease, and chronic dyspnea. Pulmonary diseases of the aging population have a negative impact on morbidity and mortality and quality of life and increase the burden on health care costs. Pharmacological treatment remains the standard of care, but polypharmacy in the older patients can be an issue and has been associated with negative consequences. Integrative or nonpharmacological approaches can be used in conjunction with conventional therapy and can decrease dependence on pharmacological drugs. Integrative approaches include nutrition, breathing exercises, yoga, acupuncture, use of botanicals and supplements, tai chi, and mind–body therapy. This chapter examines the evidence for integrative or nonpharmacological approaches and provides recommendations for their use in pulmonary diseases of older adults.
Book chapters on the topic "Quality of life of patients with bronchial asthma"
1
Mroczek, Bożena, Katarzyna Parzuchowska, Maria Jasińska-Starczewska, Tomasz Grodzki, and Donata Kurpas. "Relationships Between Quality of Life in the Psychological Domain, Acceptance of Illness, and Healthcare Services in Patients with Asthma." In Influenza and Respiratory Care, 49–60. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/5584_2016_192.
Full text
2
Labrecque, Manon, Roberto Castaño, Grégory Moullec, Ignacio Ansottegui, and Denyse Gautrin. "Occupational Asthma." In Asthma, 172–90. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199918065.003.0014.
Full textAbstract:
Work-related asthma can be divided in two major entities: work-exacerbated asthma and occupational asthma. Occupational asthma is further split into two subtypes: sensitizer-induced occupational asthma and irritant-induced asthma, which includes reactive airway dysfunction syndrome. The patient’s medical history (type of symptoms and timing) is not sufficient to diagnose occupational asthma. The diagnosis requires an objective confirmation of asthma and of work-related functional changes. Psychological distress, health-related quality-of-life impairment, and comorbid psychiatric disorder are frequent in patients with work-related asthma or work-related asthma symptoms and have to be considered in the evaluation and treatment. Many areas of research are still needed to understand the complexity of work-related asthma.
3
Naclerio, Robert M., and Ruby Pawankar. "Allergic Rhinitis." In Asthma, 231–43. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199918065.003.0018.
Full textAbstract:
Allergic rhinitis is the most common atopic disease, with an increasing prevalence worldwide. It is an immunoglobulin E–mediated inflammatory disease of the nasal mucosa, characterized by symptoms of nasal itching, sneezing, runny nose, and stuffy nose. The stuffy nose is the most burdensome symptom to patients, but the itch and sneeze are the most characteristic. Although it is not a fatal disease, allergic rhinitis has a negative impact on the patient’s quality of life (QOL), which is detected not only on disease-specific QOL measures but also on general QOL measures such as the SF36. Sleep, presenteeism, mood and cognition, and participation in sports and leisure activities are all affected, causing a great physical and financial burden on the patient.
4
Pope, Chelle, Richard D. deShazo, and Monroe James King. "Asthma Over 65." In Asthma, 441–52. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199918065.003.0032.
Full textAbstract:
With the worldwide increase in the older population and the growing prevalence of asthma, it is no surprise that asthma in the elderly is also an increasing problem. Insufficient data exist to make firm conclusions on many important issues about this condition. Seniors with asthma often have coexisting and comorbid conditions, and the combination of age and illness has precluded, in general, their participation in clinical trials. Other important variables in this population include differences in perception, interpretation, and response to the symptoms of airway obstruction. Many patients mistakenly believe that wheeze and dyspnea are normal, and they commonly decrease their activity, a response that can induce further social isolation and a decreased quality of life. Coupled with the challenge of misdiagnosis or underdiagnosis are the potential problems associated with side effects from medications, drug–drug interactions, problems appropriately using medications, and compliance. This chapter identifies the prevalence of asthma, which affects decisions about therapy, and the important questions in this age group yet to be answered.
5
Riley, Craig M., Jessica Bon, and Alison Morris. "Chronic obstructive pulmonary disease and asthma." In Oxford Textbook of Global Public Health, edited by Roger Detels, Quarraisha Abdool Karim, Fran Baum, Liming Li, and Alastair H. Leyland, 43–56. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198816805.003.0061.
Full textAbstract:
Chronic obstructive pulmonary disease (COPD) and asthma are highly prevalent, non-malignant respiratory conditions that have increased dramatically in the past half century, both in high-income and low-middle-income countries. COPD is the fourth leading cause of death worldwide, and both COPD and asthma have a profound impact on quality of life for patients and their families. Tobacco smoke remains the single most important cause of COPD, but occupational and indoor exposures have increasingly been recognized as risk factors, especially among middle- and low-income individuals. Different patterns of genetic susceptibility independent of exposure result in variability of disease expression with many patients not developing clinical COPD, although they may still develop respiratory symptoms. COPD prevalence differs greatly between countries even when controlling for smoking rates. While much progress has been made in understanding biological pathways involved in asthma, the understanding of why asthma initially develops remains elusive. Although a large number of potential risk factors have been identified, none can explain the global increases in asthma prevalence observed over the last few decades. Prevalence trends between countries have also varied, with some countries continuing to experience increases in asthma rates and some rates levelling off or even declining. These trends cannot be explained by divergent epidemiological methods or population makeup alone. Asthma control, especially for severe asthmatics and for those with non-allergic phenotypes, remains a public health problem with more efficient interventions needed to encourage smoking cessation, improve air quality, and reduce allergen exposure.
6
"Care of adults with long-term conditions." In Oxford Handbook of Primary Care and Community Nursing, edited by Judy Brook, Caroline McGraw, and Val Thurtle, 597–676. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198831822.003.0011.
Full textAbstract:
Multiple comorbidities necessitate care from a number of healthcare providers. Continuity of care is important for both patient satisfaction and quality of life. This chapter outlines primary care for adults with a variety of conditions, including osteoarthritis, rheumatoid arthritis, lower back pain, asthma and acute asthma, and stable and chronic obstructive pulmonary disease. It covers drugs commonly used in the treatment of respiratory conditions, including long-term oxygen and nebulizers. It then goes on to cover coronary heart disease, angina, hypertension, cardiac rehabilitation, heart failure, abnormal cardiac rhythms and atrial fibrillation, patients on anticoagulant therapies, and drugs used in cardiovascular diseases. The chapter also includes information on anaemia, varicose veins, diabetes, multiple sclerosis, motor neurone disease, and Parkinson’s disease.
Conference papers on the topic "Quality of life of patients with bronchial asthma"
1
Szentes, Boglárka, Larissa Schwarzkopf, Nicola Lehbert, Michael Wittmann, Rupert Wagner, Dennis Nowak, Hermann Faller, Michael Schuler, and Konrad Schultz. "Suitable questionnaires to measure quality of life in patients with asthma bronchial undergoing pulmonary rehabilitation." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa3648.
Full text
2
Eva, Eva, Ritesh Netam, Anjana Talwar, Anant Mohan, Raj Kumar Yadav, Saurabh Mittal, Hanjabam Barun Sharma, and Sanjay Patel. "Effect of a short-term yoga-based lifestyle intervention on lung function and quality of life in bronchial asthma patients." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa3974.
Full text
3
Hryhus, I., and Y. Pelekh. "EFFICIENCY OF PSYCHOPHYSICAL REHABILITTION OF PATIENTS WITH MILD PERSISTENT BRONCHIAL ASTHMA." In PSYCHOLOGICAL HEALTH OF THE PERSON: LIFE RESOURCE AND LIFE POTENTIAL. Verso, 2017. http://dx.doi.org/10.20333/2541-9315-2017-402-415.
Full text
4
Perelman, N. L., and V. P. Kolosov. "Gender Determinants of Health-Related Quality of Life in Asthma Patients." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4766.
Full text
5
Chung, Jae Ho, and Chang Hoon Han. "Quality of Life in Asthma Patients: A Nationwide Population-Based Study." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa3559.
Full text
6
Johnston, Rachel H., Elizabeth Flude, and Andrew Menzie-Gow. "Physiotherapy Intervention Improves Quality Of Life In Patients With Severe Asthma." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2755.
Full text
7
Chen, Hubert, Miriam M. Cisternas, Patricia P. Katz, Mark D. Eisner, Theodore A. Omachi, Edward H. Yelin, and Paul D. Blanc. "Assessing Health-related Quality Of Life In Patients With Asthma And Rhinitis." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5795.
Full text
8
Hashimoto, Simone, Jacob K. Sont, Anneke ten Brinke, Marijke Amelink, Peter J. Sterk, and E. H. Bel. "Psychological Factors Contributing To Asthma Control And Asthma Related Quality Of Life In Patients With Severe Prednisone-Dependent Asthma." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3796.
Full text
9
Lertsinudom, Sunee, and Kesarin Choopanyalert. "Clinical outcomes and quality of life of asthma patients in Asthma Clinic, Tertiary Care Hospital in Thailand." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa1241.
Full text
10
Utami, Pinasti, Bangunawati Rahajeng, Razmi Wulan Diastuti, M. T. Ghozali, Ingenida Hadning, Nurul Maziyyah, Indriastuti Cahyaningsih, and Salmah Orbayinah. "Prospective Study: Study of Asthma Therapy and the Relationship Between Asthma Control Levels and Quality of Life of Asthma Patients." In 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020). Paris, France: Atlantis Press, 2021. http://dx.doi.org/10.2991/ahsr.k.210115.097.
Full text